




# City of Seattle Boards & Commissions Notice of Appointment

<b>Appointee Name:</b> <i>Navin Robert Charles Pinto</i>		
<b>Board/Commission Name:</b> <i>Community Police Commission</i>		<b>Position Title:</b> <i>Member</i>
<input checked="" type="checkbox"/> <b>Appointment</b> OR <input type="checkbox"/> <b>Reappointment</b>	<b>City Council Confirmation required?</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
<b>Appointing Authority:</b> <input checked="" type="checkbox"/> City Council <input type="checkbox"/> Mayor <input type="checkbox"/> Other: <i>Fill in appointing authority</i>	<b>Term of Position: *</b> 1/1/2019 <b>to</b> 12/31/2021  <input checked="" type="checkbox"/> <i>Serving remaining term of a vacant position</i>	
<b>Residential Neighborhood:</b> <i>Maple Leaf</i>	<b>Zip Code:</b> <i>98115</i>	<b>Contact Phone No.:</b> [REDACTED]
<b>Background:</b> <i>Navin Pinto, MD, serves as an attending physician at Seattle Children's Hospital and an Associate Professor of Pediatrics at the University of Washington. He has spent his career advocating for the vulnerable and underserved. In addition to caring for children with cancer, he is a researcher actively involved in evaluating new therapies for vulnerable populations. He has held several faculty and medical positions.</i>		
<b>Authorizing Signature (original signature):</b>   <b>Date Signed (appointed):</b> <i>2/22/2021C</i>	<b>Appointing Signatory:</b> <i>Lisa Herbold</i> <i>Seattle City Councilmember</i>	


\*Term begin and end date is fixed and tied to the position and not the appointment date.

# CURRICULUM VITAE

Navin Robert Charles Pinto, MD

## 1. CONTACT INFORMATION

Navin Pinto, MD  
Associate Professor of Pediatrics



## 2. PERSONAL DATA



## 3. EDUCATION

1997-2001 BA, Biology. Saint Louis University, St. Louis, MO  
2001-2005 MD, Saint Louis University, St. Louis, MO

## 4. POSTGRADUATE TRAINING

2005-2008 Residency, Department of Pediatrics, The University of Chicago, Chicago, IL  
2008-2011 Fellowship, Section of Pediatric Hematology/Oncology, The University of Chicago, Chicago, IL  
2009-2011 Postdoctoral Fellowship, Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL

## 5. FACULTY POSITIONS HELD

2011-2013 Instructor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, The University of Chicago, Chicago, IL  
2013-2015 Assistant Professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, The University of Chicago, Chicago, IL  
2015- Associate Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle, WA

## 6. HOSPITAL POSITIONS HELD

2009-2015 Clinical Associate, Department of Pediatrics, Section of Pediatric Emergency Medicine, Comer Children's Hospital, The University of Chicago, Chicago, IL  
2015- Attending Physician, Seattle Children's Hospital, Seattle, WA  
2016-2019 Outpatient Medical Director, Division of Hematology/Oncology, Seattle Children's Hospital, Seattle, WA

## 7. HONORS

2001	<i>Summa cum laude</i> , Saint Louis University
2005	Alpha Omega Alpha Medical Honors Society, Saint Louis University School of Medicine
2005	Rodney M. Coe Distinction in Community Service, Saint Louis University School of Medicine
2008	Intern of the Year, The University of Chicago Department of Pediatrics
2008	Senior Resident of the Year, The University of Chicago Department of Pediatrics
2008	November Employee of the Month, The University of Chicago Medical Center
2009	Fellow Teaching Award, The University of Chicago, Department of Pediatrics
2010	American Society of Clinical Oncology Young Investigator Award
2010	Best Poster Presentation, Clinical Category, Advances in Neuroblastoma Research Meeting, Stockholm, Sweden
2010-2011	St. Baldrick's Foundation Fellowship
2011	Scholar-in-Training Award, American Association for Cancer Research
2012	Best Translational Poster Presentation by Faculty – The University of Chicago Department of Pediatrics Research Day
2011-2017, 2018-2019	National Institutes of Health Loan Repayment Program
2011-2013	Cancer Research Foundation Young Investigator Award
2012-2016	St. Baldrick's Foundation Scholar Award
2013	Best Translational Poster Presentation by Faculty – The University of Chicago Department of Pediatrics Research Day
2014	Best Translational Poster Presentation by Faculty – The University of Chicago Department of Pediatrics Research Day
2014	Best Basic Science Poster Presentation by Faculty – The University of Chicago Department of Pediatrics Research Day
2018	Visiting Professor, Committee on Clinical Pharmacology and Pharmacogenomics – The University of Chicago

## 8. BOARD CERTIFICATION

2008-	American Board of Pediatrics
2012-	American Board of Clinical Pharmacology
2013-	American Board of Pediatrics – Pediatric Hematology/Oncology

## 9. CURRENT LICENSES TO PRACTICE

2008-2017	Illinois State Medical License #036.120330
2008-2017	Illinois State Controlled Substances License #336.081540
2008-2017	Drug Enforcement Agency License #FP0816201
2015-	Washington State Medical License #MD60591778

## 10. PROFESSIONAL ORGANIZATIONS

American Society of Clinical Oncology  
Children's Oncology Group  
American Society of Pediatric Hematology/Oncology  
New Approaches to Neuroblastoma Therapy  
Advances in Neuroblastoma Research Association

## 11. TEACHING RESPONSIBILITIES

### (a) Medical students and students in allied health professionals

Table 1: Courses Taught

Course	Title	Credits	Years	Students	Responsibility
CCTS 40004	Advanced Clinical Pharmacology I	3.3	2014	6	Co-Instructor (50%)

### (b) Pediatric residents

2009-2015 University of Chicago Comer Children's Hospital, Pediatric Emergency Medicine. Clinical preceptor for pediatric residents, medical students and fellows.

2011-2015 University of Chicago Comer Children's Hospital, Pediatric Hematology/Oncology/Stem Cell Transplant Inpatient Service. Clinical preceptor for pediatric residents and medical students.

Table 2: Recurring Pediatric Resident Lectures

Course	Title	Credits	Years	Students	Responsibility
Peds Morning Report	Joel G. Schwab Rounds (2/year)	N/A	2014-	60-80	Leader of multidisciplinary presentation of an interesting patient

### Mentorship for residents

2014-2015 Steven Carey, MD, PhD  
Isolation of circulating cancer-associated cells from patients with relapsed/refractory neuroblastoma

### (c) Subspecialty fellows

2011-2015 University of Chicago Comer Children's Hospital, Pediatric Hematology/Oncology/Stem Cell Transplant Inpatient Service. Clinical preceptor for fellows.

2015- Seattle Children's Hospital, Clinical preceptor for fellows

Table 3: Recurring Pediatric Hematology/Oncology Resident/Fellow Lectures

Course	Title	Credits	Years	Students	Responsibility
Core Lecture Series	Core Lectures (5/year) 1. Neuroblastoma 2. Osteosarcoma 3. Ewing Sarcoma 4. Rhabdomyosarcoma 5. Non-rhabdo Soft Tissue Sarcoma	N/A	2011-	6	Lecturer

### Mentorship for fellows

2013-2015 Joseph Henderson, DO (Pediatric Hematology/Oncology)  
Scholarship Oversight Committee

2014-2015 Elizabeth Sokol, MD (Pediatric Hematology/Oncology)  
"A Phase I trial of OTS167, an inhibitor of Maternal Embryonic Leucine Zipper Kinase, in children with relapsed or refractory solid tumors" (Role – study PI)

- 2016-2019 Jay Sarthy, MD, PhD (Pediatric Hematology/Oncology)  
Clinical Mentorship Committee
- 2018-2020 Cassie Chou, MD, PhD; Erin Crotty, MD; Mallory Taylor, MD (Pediatric Hematology/Oncology)  
Scholarship Oversight Committee

*(d) Other venues*

*Laboratory mentorship*

- 2010-2012 Nirav Antao, research technician  
2011 Jeffrey Lei, summer research technician  
2012 Ashley Paquin, summer research technician  
2012-2013 Jaime Myers, research technician

*Clinical research mentorship*

- 2017-2018 Sanjana Nelluri, undergraduate research assistant  
2019 - Anurekha Gollapudi, MD, research fellow

**12. EDITORIAL RESPONSIBILITIES**

- 2018 Guest editor, *Children*  
2019 - Editorial Board, *Children*

**13. SPECIAL NATIONAL RESPONSIBILITIES**

- 2012- Member, Biology Committee, New Approaches to Neuroblastoma Therapy (NANT) Consortium  
2013- Grant reviewer, St. Baldrick's Foundation  
2014- Member, Children's Oncology Group Relapsed High-risk Neuroblastoma Task Force  
2014- Member, Protocol Writing Committee, Genomic Assessment Informing New Therapies (GAIN) Consortium  
2016- Study Chair, Children's Oncology Group ADVL1621, "A Phase I/II Study of Pembrolizumab MK-3475 in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma KEYNOTE-051"  
2016- Study Vice-Chair, Children's Oncology Group ANBL1232, "Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma"  
2016- Pediatric Study Co-Chair, American Society of Clinical Oncology Targeted Agent Profiling and Utilization Registry (TAPUR)  
2017- Publications Committee, Targeted Agent Profiling and Utilization Registry (TAPUR)  
2017- Steering Committee, Targeted Agent Profiling and Utilization Registry (TAPUR)  
2017- Member, Professional Development Committee, American Society of Pediatric Hematology/Oncology  
2017- Member, Target and Agent Prioritization Committee, Children's Oncology Group APEC1621, Pediatric NCI MATCH  
2018- Steering Committee Member, ANBL1821, "A Randomized Phase II study of irinotecan/temozolomide/dinutuximab/GMCSF with or without difluoromethylornithine (DFMO) in patients with relapsed or refractory high-risk neuroblastoma"  
2018- Site Principal Investigator, New Approaches to Neuroblastoma Therapy (NANT) Consortium

2018-2020- Co-Leader, High-Risk Neuroblastoma Task Force, Children's Oncology Group  
Site Principal Investigator, Children's Oncology Group Pediatric Early Phase-Clinical  
Trial Network (PEP-CTN)

#### 14. SPECIAL LOCAL RESPONSIBILITIES

2011-2015 Member, Committee on Clinical Pharmacology and Pharmacogenomics, The University  
of Chicago  
2014-2015 Associate Junior Faculty Scholar, Bucksbaum Institute for Clinical Excellence, The  
University of Chicago  
2015 Co-Director, University of Chicago Comer Children's Hospital Chicago White Sox  
Teen Program  
2016-2018 Medical Informatics Committee, Seattle Children's Hospital  
2017-2019 Outpatient Medical Director, Seattle Children's Hospital Cancer and Blood Disorders  
Center

#### 15. RESEARCH FUNDING

##### Active Funding

10/1/17 – 9/30/20  
Total direct cost: \$100,000.  
Andrew McDonough B+ Foundation “**STRIVe-02 and BrainChild03: B7-H3 CAR T  
Cell Therapy for Relapsed and Refractory B7-H3 Expressing Solid Tumors  
(Inclusive of Brain Tumors) in Children and Young Adults.**”  
(Role: PI)

07/01/19 – 06/30/21  
Total Direct Cost: \$62,869.  
Prostate Cancer Foundation “**LICAM Chimeric Antigen Receptor T Cell Therapy  
for Small Cell Neuroendocrine Prostate Cancer.**”  
(Role: Co-Investigator)

##### Completed Funding

7/1/10 – 12/31/11  
Total direct cost: \$50,000  
Conquer Cancer Foundation of the American Society of Clinical Oncology Young  
Investigator Award “**Population-specific Genetic Variants Important in  
Susceptibility to Cyclophosphamide in Pediatric Patients.**” Project period:, P.I. M.  
Eileen Dolan.  
(Role: co-investigator, mentored training award) Total direct cost: \$50,000. Annual  
salary recovery or effort: 5%.

7/1/10 – 6/30/12  
Total direct cost: \$142,658.  
St. Baldrick's Foundation Fellowship “**Population-specific Genetic Variants  
Important in Susceptibility to Cyclophosphamide**” P.I. M. Eileen Dolan.  
Annual salary recovery or effort: 80%.  
(Role: co-investigator, mentored training award)

12/1/11 – 12/31/15

Total direct cost: \$75,000

Cancer Research Foundation Young Investigator Award “**Population-specific Genetic Variants Important in Susceptibility to Cyclophosphamide in Pediatric Patients**”

Annual salary recovery or effort: 5%.

2/1/15 – 1/31/17

Total direct cost: \$150,000

Super Jake Foundation “**Germline Genetic Variations, Pharmacogenomics, and Impacting Cancer Outcomes.**” Annual salary recovery or effort: 5%.

(Role: PI).

1/1/15 – 12/31/17

Total direct cost: \$400,000

Necdet Ersoy Foundation “**Genomics of Risk Assessment and Anticancer Therapy in Children (GREAT KIDS).**” Annual salary recovery or effort: 5%.

(Role: PI).

7/1/12 – 6/30/17

Total direct cost: \$660,000

St. Baldrick’s Foundation Scholar Award “**Genomics of Treatment Failure in Neuroblastoma.**” Annual salary recovery or effort: 50%.

(Role: PI).

## 16. BIBLIOGRAPHY

### (a) Manuscripts in refereed journals:

1. **Pinto N**, Ludeman SM, Dolan ME. Drug Focus: Pharmacogenetic Studies Related to Cyclophosphamide-based Therapy. *Pharmacogenomics*. 2009; 10(12): 1897-903.
2. Henderson TO, Bhatia S, **Pinto N**, London WB, McGrady P, Crotty C, Sun C-L, Cohn SL. Racial and Ethnic Disparities in Risk and Survival in Children with Neuroblastoma: A Children’s Oncology Group (COG) Study. *J Clin Onc*. 2011; 29(1): 76-82.
3. **Pinto N**, Ratain MJ. Pharmacogenomics in Cancer Care: Adding Some Science to the Art of Medicine. *Personalized Medicine in Oncology*. 2012; 1(4): 56-62.
4. **Pinto N**, Dolan ME. Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes. *Curr Drug Metab*. 2011; 12(5): 487-97.
5. **Pinto N**, Cohn SL, Dolan ME. Using germline genomics to individualize pediatric cancer treatments. *Clin Cancer Res*. 2012; 18(10): 2791-800.
6. Gamazon ER, **Pinto N**<sup>\*</sup>, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. *J Natl Cancer Inst*. 2013; 105(4): 302-9. <sup>\*</sup>equal contribution

7. Staley S, Hageman, JR, **Pinto N**, Khan N. An arresting sickle cell disease complication. *Pediatr Ann.* 2013; 42(11): 448-51.
8. **Pinto N**, Cipkala DA, Ladd PE, Pu Y, Cohn SL. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretinoin alone or observation. *Pediatr Blood Cancer.* 2014; 61(6): 1104-6.
9. **Pinto N\***, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. *Clin Pharmacol Ther.* 2014; 95(6): 644-52. \*equal contribution
10. Applebaum MA, Henderson TO, Lee SM, **Pinto N**, Volchenbom SL, Cohn SL. Second Malignancies in Patients with Neuroblastoma: The Effects of Risk-Based Therapy. *Pediatr Blood Cancer.* 2015: 62(1): 128-33.
11. Madian AG, Panigrahi A, Perera MA, **Pinto N**. Case report: inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. *BMC Pharmacol Toxicol.* 2014: 15(1): 69.
12. **Pinto N**, Applebaum MA, Volchenbom SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiemacher G, Park JR, Valteau-Couanet D, Pearson ADJ, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *J Clin Oncol.* 2015; Sep 20;33(27):3008-17.
13. **Pinto N**, Volchenbom SL, Skol AD, Rhodes L, Doan A, Fein-Levy C, Lipton JM, Cunningham JM, Onel K. Establishing a Translational Genomics Infrastructure in Pediatric Cancer: the GREAT KIDS Experience. *Personalized Med.* 2015: 12(3): 221-9.
14. Darlington WS, **Pinto N**, Hecktman HM, Cohn SL, Labelle JL. Stem cell transplant-associated Wernicke encephalopathy in a patient with high-risk neuroblastoma. *Pediatr Blood Cancer.* 2015 Dec;62(12):2232-4.
15. **Pinto N**, Hawkins DS. Second Malignant Neoplasms in Rhabdomyosarcoma: Victims of Our Own Success or an Underlying Genetic Predisposition Syndrome?. *Pediatr Blood Cancer.* 2016 Feb;63(2):189-90.
16. **Pinto N**, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. *Pediatr Blood Cancer.* 2016 Jun;63(6):1019-23.
17. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, **Pinto N**, Volchenbom SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. *Eur J Cancer.* 2017 Feb;72: 177-185.
18. Sokol E, Huang E, Pytel P, Cohn SL, **Pinto N**. Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. *Pediatr Blood Cancer.* 2017 Mar; 64(3).



19. **Pinto N**, Park JR, Murphy E, Yearley J, McClanahan T, Annamalai L, Hawkins DS, Rudzinski ER. Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors. *Pediatr Blood Cancer*. 2017 Nov; 64(11).
20. Ceppi F, Rivers J, Annesley C, **Pinto N**, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. *Transfusion*. 2018 Mar 13. doi: 10.1111/trf.14569. [Epub ahead of print]
21. **Pinto N**, DuBois SG, Marachelian A, Diede SJ, Taraseviciute, A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. Phase I Study of Vorinostat in Combination with Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial. *Pediatr Blood Cancer*. 2018 Jul; 65(7):e27023.
22. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, **Pinto N**, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2018 Aug;82(2):309-317.
23. Elzembely MM, Dahlberg AE, **Pinto N**, Leger KJ, Chow EJ, Park JR, Carpenter PA, Baker KS. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue. *Pediatr Blood Cancer*. 2018 Aug 27:e27421.
24. Sokol EA, Engelmann R, Kang W, **Pinto N**, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG 3rd, Volchenboum S. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. *Pediatr Blood Cancer*. 2018 Dec;65(12):e27417.
25. Elzembely MM, Park JR, Riad KF, Sayed HA, **Pinto N**, Carpenter PA, Baker KS, El-Haddad A. Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources. *J Glob Oncol*. 2018 Sep;(4):1-12.
26. Tedesco KT, Sarthy J, **Pinto N**, Boos MD. Acute enlargement of a vascular plaque and gait changes in a young girl. *BMJ*. 2018 Nov 28;363:k4679.
27. Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, **Pinto N**, Kim ES, Schilsky RL. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *JCO Precis Oncol*. 2018;2018.
28. **Pinto N**, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). *Eur J Cancer*. 2019 May;112:66-79.
29. Georger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, **Pinto N**. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. *Lancet Oncol*. 2020 Jan;21(1):121-133.

30. Spencer K, Romberg E, **Pinto N**. Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma. *Pediatr Blood Cancer*. 2020 Apr;67(4):e28147.
31. Davis JL, Vargas SO, Rudzinski ER, López Marti JM, Janeway K, Forrest S, Winsnes K, **Pinto N**, Yang SE, VanSandt M, Boyd TK, Corless CL, Liu YJ, Surrey LF, Harris MH, Church A, Al-Ibraheemi A. Recurrent RET Gene Fusions in Pediatric Spindle Mesenchymal Neoplasms. *Histopathology*. 2020 Jun;76(7):1032-1041.

(b) *Book Chapters*

1. **Pinto N**, Onel K. Towards Personalized Medicine in Pediatric Cancer: Genome-Wide Strategies to Investigate Cancer Risk and Response to Therapy. In: MacKinnon AC. *Pediatric Neoplasia*. 2012 ed. New York, NY: Humana Press; 2012.
2. Sokol E, **Pinto N**. Molecular Targeted Therapy for Pediatric Neoplasms. In Furtado LV. *Precision Molecular Pathology of Neoplastic Pediatric Diseases*. 2018 ed. New York, NY: Springer Nature 2018.

(c) *Published books, videos, software*

N/A

(d) *Other publications*

N/A

(e) *Manuscripts Submitted*

N/A

## 17. OTHER

(a) *Invited speaking*

- |      |   |
|------|---|
| 2010 | Oral Abstract, “Survival Variability by Race and Ethnicity in Neuroblastoma: A Children’s Oncology Group (COG) Study.” Advances in Neuroblastoma Research, Stockholm, Sweden                                      |
| 2011 | Invited Speaker, “A Foot In Both Worlds: Caring For Children With Life-Threatening Illness.” Pediatric Palliative Care: State of the Practice, Barrington, IL   |
| 2012 | Oral Abstract, “Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma.” American Society of Clinical Oncology Annual Meeting, Chicago, IL. |
| 2012 | Plenary Talk, “Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma.” Advances in Neuroblastoma Research, Toronto, ON, Canada.            |
| 2013 | Grand Rounds “Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Drug-Specific Mechanisms of Treatment Failure in Neuroblastoma Patients.” The University of Chicago Department of Pediatrics.   |
| 2016 | High-Risk Neuroblastoma. Seattle Children’s Hospital Nursing Education Day  |
| 2016 | Oral Abstract, “Pharmacogenetics of Treatment Response in High-Risk Neuroblastoma: A Children’s Oncology Group Study.” Advances in Neuroblastoma Research, Cairns, Australia                                      |
| 2017 | Invited Speaker, “High-Risk Neuroblastoma, An Update.” Pediatric Oncology Grand Rounds, Tata Memorial Hospital, Mumbai, India.  |
| 2018 | Visiting Professor, University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics Annual Fellow’s Lecture, Chicago, IL.   |
| 2018 | Invited Speaker, Pediatrics Grand Rounds, University of New Mexico Comprehensive Cancer Center. Albuquerque, NM.  |

- 2019 Invited Speaker, Seattle Women in Tech Regatta, Seattle, WA
- 2020 Invited Speaker, Grand Rounds, University of Arizona Department of Pediatrics, Phoenix Children's Hospital, Phoenix, AZ
- 2020 Invited Chair, Cellular Immunotherapy Session, International Neuroblastoma Parent Education Symposium, Virtual
- 2020 Invited Speaker, General Q&A Session, International Neuroblastoma Parent Education Symposium, Virtual

*(b) Ad hoc Journal Review*

Clinical Nephrology, Pediatric Blood and Cancer, The Pharmacogenomics Journal, Cancer Medicine, Pharmacogenetics and Genomics, Journal of Pediatric Hematology/Oncology

# Community Police Commission

21 Members: Pursuant to 125315, all members subject to City Council confirmation, 3

- 7 City Council-appointed
- 7 Mayor-appointed
- 7 Other Appointing Authority-appointed (specify):

## Roster:

*D	**G	RD	Position No.	Position Title	Name	Term Begin Date	Term End Date	Term #	Appointed By
	F		1.	Member	Asha Mohamed	1/1/20	12/31/22	2	Mayor
			2.	Member	Patricia L. Hunter	1/1/21	12/31/23	1	City Council
			3.	Public Defense	La Rond Baker	1/1/18	12/31/20	1	CPC
2	F		4.	Member	Suzette Dickerson	1/1/21	12/31/23	2	Mayor
			5.	Member	Douglas E. Wagoner	1/1/18	12/31/20	1	City Council
			6.	Civil Liberties	Prachi Vipinchandra Dave	1/1/18	12/31/20	1	CPC
	F		7.	Member	Erin B. Goodman	1/1/21	12/31/23	2	Mayor
			8.	Member	Navin Robert Charles Pinto	1/1/19	12/31/21	1	City Council
4	M		9.	Member	Austin Field	1/1/20	12/31/22	1	CPC
2	F		10.	Member	Harriett Walden	1/1/19	12/31/21	3	Mayor
			11.	Member	Vacant	1/1/19	12/31/21		City Council
7	M		12.	Member	Joseph Seia	1/1/19	12/31/21	2	CPC
9	F		13.	Member	Esther Lucero	1/1/19	12/31/21	1	Mayor
			14.	Member	Vacant	1/1/19	12/31/21		City Council
2	M		15.	SPOG	Mark Mullens	1/1/20	12/31/22	1	CPC
			16.	Member	Vacant	1/1/20	12/31/22		Mayor
3	NB	3	17.	Member	Alina Santillan	1/1/17	12/31/19	1	City Council
			18.	SPMA	Scott Bachler	1/1/20	12/31/22		CPC
			19.	Member	Colleen Echohawk	1/1/20	12/31/22	2	Mayor
			20.	Member	Tascha R. Johnson	1/1/20	12/31/22	1	City Council
2	F		21.	Member	Erica Newman	1/1/20	12/31/22		CPC

**SELF-IDENTIFIED DIVERSITY CHART**

**(1)**

**(2)**

**(3)**

**(4)**

**(5)**

**(6)**

**(7)**

**(8)**

**(9)**

	Male	Female	Transgender	NB/ O/ U	Asian	Black/ African American	Hispanic/ Latino	American Indian/ Alaska Native	Other	Caucasian/ Non- Hispanic	Pacific Islander	Middle Eastern	Multiracial
<b>Mayor</b>		6				2		2		1			2
<b>Council</b>	1	2	1			2	1						1
<b>Other</b>	4	3			1	3			1	1	1		
<b>Total</b>	5	11	1		1	9	1	2	1	2	1		3

**Key:**

**\*D** List the corresponding *Diversity Chart* number (1 through 9)

**\*\*G** List *gender*, **M**= Male, **F**= Female, **T**= Transgender, **NB**= Non-Binary **O**= Other **U**= Unknown

**RD** Residential Council District number 1 through 7 or N/A

*Diversity information is self-identified and is voluntary.*